Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 11/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | HTR1F | P30939 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229368 | 1.00 | SRC (0.42) | SRCNOD1CXCL8PTGDRPTGDR2 | |
| SCHEMBL16796191 | 0.81 | CNR2 (0.43) | SRCNOD1CXCL8HTR6 | |
| SCHEMBL25422879 | 0.80 | MTNR1B (0.55) | SRCHTR6FABP4 | |
| SCHEMBL20841436 | 0.79 | SRC (0.40) | SRCNOD1CXCL8PTGDRPTGDR2 | |
| SCHEMBL30276218 | 0.78 | CA12 (0.52) | SRCNOD1CXCL8HTR6CA12 | |
| SCHEMBL369194 | 0.78 | CA12 (0.52) | SRCNOD1CXCL8HTR6CA12 | |
| SCHEMBL16795088 | 0.76 | SRC (0.40) | SRCNOD1CXCL8HTR6HTR1A | |
| SCHEMBL20853109 | 0.75 | PTGDR2 (0.42) | SRCNOD1CXCL8PTGDRPTGDR2 | |
| SCHEMBL17927607 | 0.75 | ACLY (0.44) | SRCNOD1PTGDRPTGDR2HTR6 | |
| SCHEMBL30158830 | 0.75 | SRC (0.37) | SRCNOD1CXCL8PTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-111108105-B | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3697785-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-07-30 | — | — | US | disclosed |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2020-07-30 | — | — | US | disclosed |
| EP-3684767-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| CN-111225915-A | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-111108105-A | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019077631-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019077631-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019058393-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019058393-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | SRC 2674/4885NOD1 90/4885CXCL8 558/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | SRC 139/4885NOD1 3477/4885CXCL8 1390/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | SRC 653/4885NOD1 640/4885CXCL8 1046/4885 |
| US-20200237771-A1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | PADI4, PADI1, PADI2 | SRC 1615/4885NOD1 58/4885CXCL8 565/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | SRC 653/4885NOD1 640/4885CXCL8 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.